Anti-Microbial Nasal Spray Effective Against COVID-19 in Nonhospitalized Patients, Study Shows
Glenmark Pharmaceuticals reported that its anti-microbial nitric oxide nasal spray (NONS) had positive results in a phase 3 trial in 306 nonhospitalized adult Indian patients with COVID-19.
The anti-microbial spray reduced viral load by 94 percent in 24 hours and by 99 percent in 48 hours when compared to saline nasal spray, the company said.
Glenmark, which received marketing approval from India’s drug regulator for NONS in an accelerated approval process, plans to market NONS under the brand name FabiSpray in India. The company also plans to launch the product in other Asian markets in partnership with SaNOtize Research & Development.
About Glenmark
Glenmark Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Mumbai, India that was founded in 1977. By 2011 Glenmark had worldwide sales of $778 million, the growth was driven by Glenmark's entry into the US and European generics markets. The company focused on new drugs and biosimilars in the fields of cancer, dermatology and respiratory diseases, which it sought to monetize by partnering with major pharmaceutical companies. For the financial year 2016–2017 its sales were around 81 billion INR (ca. $1.25 billion), making it the fourth-biggest Indian pharmaceutical company.
February 10, 2022
